The Effect of Low-Level Laser Therapy on Human Leukemic Cells

Introduction: Laser phototherapy is used for the treatment of chemotherapy-induced oral mucositis in patients with leukemia, although there are limited data supporting the safety of this method. This study aimed to evaluate the effect of different doses of low-level laser on proliferation of acute myeloid leukemia (AML) cell line (KG-1a) in vitro.Methods: A plastic flask containing 5,000,000 KG-1a cultured cells was provided by Iran Pasteur Institute. KG-1a cell line has been produced from the bone marrow aspirate of a 59-year-old white male with acute myelogenous leukemia. Upon completion of the proliferation steps of KG-1a cell line, 7×104 cells were placed in 96-well tissue culture plates. All the surrounding wells were filled with Wright-Giemsa stain in order to prevent laser from scattering to the neighboring wells. In total, 28 plates were prepared using this method. After a forty-eight hours incubation period, irradiation was performed in continuous mode with an infrared laser of 810nm wavelength. After 24 hours, cells cultures were exposed to one, two, or three applications of laser irradiation. Irradiation exposures were performed at energy densities of 5, 10, and 20 J/cm2. Each experiment included 18 replicates for each application of laser and 6 replicates of negative/untreated controls. For experiments with two and three repeated exposures, the irradiation applications were separated by 48 hours. All the culture plates were incubated for seven days. Cell proliferation was evaluated using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide)  assay after seven days. Spectroscopy (620nm) was used to determine the optical density (OD) of both irradiated and control samples.Results: Significant increase in cell proliferation was seen only after two exposures at energy density of 20J/cm2 (P=0.021).Conclusion: Although LLLT is commonly used to treat radiotherapy- or chemotherapy- induced mucositis, as long as further studies demonstrate that different wavelengths and doses of laser phototherapy are safe and effective in treatment of mucositis, clinicians should remain cautious regarding the use of this treatment modality to treat patients with malignancies

Assessment of salivary and serum antioxidant status in patients with recurrent aphthous stomatitis

Objective: The aim of this study was to determine the possible association of oxidant/antioxidant status and recurrent aphthous stomatitis (RAS). Study design: The study consis ted of thirty-one patients with RAS and thirty-two healthy controls from whom saliva and blood samples were collected. Superoxide dismutase (SOD), glutathione peroxidase (GSHPx) and catalase (CAT) were measured in erythrocytes and total antioxidant status (TAS) was measured in plasma and saliva. Results: Erythrocyte SOD activity was significantly lower in RAS patients in comparison to healthy controls (P=0.012). No significant differences were found in erythrocyte GSHPx, CAT activities, and salivary and plasma TAS between RAS patients and control subjects (p>0.1). Conclusion: Changes in SOD activity may be important in the inflammatory reactions observed in RAS, but other tested defense systems such as CAT and GSHPx do not seem to play a primary role in the aetiopathogenesis of RAS. Moreover, the antioxidant system in saliva and plasma is not as affected as in erythrocytes in RAS patients, and therefore it may not be considered an appropriate indicator of the body?s total antioxidant status

Comparison of colchicine versus prednisolone in recurrent aphthous stomatitis: A double-blind randomized clinical trial

Purpose: Recurrent aphthous stomatitis (RAS) is one of the most common ulcers of the oral cavity with a reported prevalence of 5- 50%. There is still no definitive treatment for RAS; however, immunosuppressive and immunomodulant agents have been proposed. In this study, we compared the therapeutic effects of 5 mg/d prednisolone with 0.5 mg/d colchicine in the treatment of RAS. Methods: In a double-blind randomized clinical trial, 34 patients with RAS were randomly divided into two groups for treatment with prednisolone or colchicine. All patients took the medication for three months and were assessed at two weeks intervals. The groups were compared for size and number of lesions, severity of pain and burning sensation, duration of pain-free episodes and any side effects of the prescribed medicines. Both colchicine and prednisolone treatments significantly reduced RAS (p < 0.001). No significant differences in size and number of lesions, recurrence and severity of pain and duration of pain-free period were seen between the two treatment groups. Colchicine (52.9%) had significantly more side effects than prednisolone (11.8%). Conclusion: Low dose prednisolone and colchicine were both effective in treating RAS. Given that the two therapies had similar efficacy, yet colchicine was associated with more side effects, , 5mg/d of prednisolone seems to be a better alternative in reducing the signs and symptoms of the disease